Clinical study design of a multicenter, prospective, randomized controlled clinical trial on clinical efficacy of Toripalimab adjuvant therapy on esophageal squamous cell carcinoma patients with post-neoadjuvant positive lymph node staging / 中华消化外科杂志
Chinese Journal of Digestive Surgery
; (12): 655-659, 2021.
Article
en Zh
| WPRIM
| ID: wpr-908420
Biblioteca responsable:
WPRO
ABSTRACT
Neoadjuvant therapy has become the first choice for locally advanced esophageal carcinoma. Patients with post-neoadjuvant positive lymph node staging (ypN+) have poor prognosis, and there is no effective adjuvant therapy. Programmed death protein-1 (PD-1) antibody can obtain better clinical efficacy in the treatment of advanced esophageal cancer. The authors designed a multicenter, prospective, randomized controlled clinical trial of Toripalimab (PD-1 antibody) adjuvant therapy on esophageal squamous cell carcinoma patients with ypN+ after the treatment of neoadjuvant chemotherapy combined with surgical resection, in order to provide clinical practices for the adjuvant treatment of ypN+ patients.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Clinical_trials
Idioma:
Zh
Revista:
Chinese Journal of Digestive Surgery
Año:
2021
Tipo del documento:
Article